No association of Gaucher disease with COVID-19-related outcomes: a nationwide cohort study.
COVID-19
Gaucher
SARS-CoV-2
coronavirus
mortality
national
Journal
Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
revised:
16
12
2021
received:
30
10
2021
accepted:
16
12
2021
pubmed:
24
12
2021
medline:
24
3
2022
entrez:
23
12
2021
Statut:
ppublish
Résumé
It is well documented that patients with chronic metabolic diseases, such as diabetes and obesity, are adversely affected by the COVID-19 pandemic. However, when the subject is rare metabolic diseases, there are not enough data in the literature. To investigate the course of COVID-19 among patients with Gaucher disease (GD), the most common lysosomal storage disease. Based on the National Health System data, a retrospective cohort of patients with confirmed (polymerase chain reactionpositive) COVID-19 infection (n = 149 618) was investigated. The adverse outcomes between patients with GD (n = 39) and those without GD (n = 149 579) were compared with crude and propensity score-matched (PSM) groups. The outcomes were hospitalisation, the composite of intensive care unit (ICU) admission and/or mechanical ventilation and mortality. The patients with GD were significantly older and had a higher frequency of hypertension (HT), Type 2 diabetes mellitus (T2DM), dyslipidaemia, asthma or chronic obstructive pulmonary disease, chronic kidney disease, coronary artery disease, heart failure and cancer. Although hospitalisation rates in Gaucher patients were found to be higher in crude analyses, the PSM models (model 1, age and gender matched; model 2, matched for age, gender, HT, T2DM and cancer) revealed no difference for the outcomes between patients with GD and the general population. According to multivariate regression analyses, having a diagnosis of GD was not a significant predictor for hospitalisation (P = 0.241), ICU admission/mechanical ventilation (P = 0.403) or mortality (P = 0.231). According to our national data, SARS-CoV-2 infection in patients with GD does not have a more severe course than the normal population.
Sections du résumé
BACKGROUND
It is well documented that patients with chronic metabolic diseases, such as diabetes and obesity, are adversely affected by the COVID-19 pandemic. However, when the subject is rare metabolic diseases, there are not enough data in the literature.
AIM
To investigate the course of COVID-19 among patients with Gaucher disease (GD), the most common lysosomal storage disease.
METHODS
Based on the National Health System data, a retrospective cohort of patients with confirmed (polymerase chain reactionpositive) COVID-19 infection (n = 149 618) was investigated. The adverse outcomes between patients with GD (n = 39) and those without GD (n = 149 579) were compared with crude and propensity score-matched (PSM) groups. The outcomes were hospitalisation, the composite of intensive care unit (ICU) admission and/or mechanical ventilation and mortality.
RESULTS
The patients with GD were significantly older and had a higher frequency of hypertension (HT), Type 2 diabetes mellitus (T2DM), dyslipidaemia, asthma or chronic obstructive pulmonary disease, chronic kidney disease, coronary artery disease, heart failure and cancer. Although hospitalisation rates in Gaucher patients were found to be higher in crude analyses, the PSM models (model 1, age and gender matched; model 2, matched for age, gender, HT, T2DM and cancer) revealed no difference for the outcomes between patients with GD and the general population. According to multivariate regression analyses, having a diagnosis of GD was not a significant predictor for hospitalisation (P = 0.241), ICU admission/mechanical ventilation (P = 0.403) or mortality (P = 0.231).
CONCLUSION
According to our national data, SARS-CoV-2 infection in patients with GD does not have a more severe course than the normal population.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
379-385Informations de copyright
© 2021 Royal Australasian College of Physicians.
Références
Nalysnyk L, Rotella P, Simeone JC, Hamed A, Weinreb N. Gaucher disease epidemiology and natural history: a comprehensive review of the literature. Hematology. 2017; 22: 65-73.
Svennerholm L, Håkansson G, Månsson JE, Nilsson O. Chemical differentiation of the Gaucher subtypes. Prog Clin Biol Res 1982; 95: 231-52.
Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet 2020; 395: 1763-70.
Chung CCY, Wong WHS, Fung JLF, Kong RDH, Chung BHY. Impact of COVID-19 pandemic on patients with rare disease in Hong Kong. Eur J Med Genet 2020; 63: 104062.
Sánchez-García JC, Cortés-Martín J, Rodríguez-Blanque R, Marín-Jiménez AE, Montiel-Troya M, Díaz-Rodríguez L. Depression and anxiety in patients with rare diseases during the COVID-19 pandemic. Int J Environ Res Public Health 2021; 18: 3234.
Chung CCY, Wong WHS, Chung BHY. Hospital mortality in patients with rare diseases during pandemics: lessons learnt from the COVID-19 and SARS pandemics. Orphanet J Rare Dis 2021; 16: 361.
Mistry P, Balwani M, Barbouth D, Burrow TA, Ginns EI, Goker-Alpan O et al. Gaucher disease and SARS-CoV-2 infection: emerging management challenges. Mol Genet Metab 2020; 130: 164-9.
O'Driscoll M, Santos GRD, Wang L, Cummings DAT, Azman AS, Paireau J et al. Age-specific mortality and immunity patterns of SARS-CoV-2. Nature 2021; 590: 140-5.
Hussain A, Mahawar K, Xia Z, Yang W, EL-Hasani S. Obesity and mortality of COVID-19. Meta-analysis. Obes Res Clin Pract 2020; 14: 295-300.
Sonmez A, Demirci I, Haymana C, Tasci I, Dagdelen S, Salman S et al. Clinical characteristics and outcomes of COVID-19 in patients with type 2 diabetes in Turkey: a nationwide study (TurCoviDia). J Diabetes 2021; 13: 585-95.
Tian W, Jiang W, Yao J, Nicholson CJ, Li RH, Sigurslid HH et al. Predictors of mortality in hospitalized COVID-19 patients: a systematic review and meta-analysis. J Med Virol 2020; 92: 1875-83.
Neufeld EF. Lysosomal storage diseases. Annu Rev Biochem 1991; 60: 257-80.
Fierro L, Nesheiwat N, Naik H, Narayanan P, Mistry PK, Balwani M. Gaucher disease and SARS-CoV-2 infection: experience from 181 patients in New York. Mol Genet Metab 2021; 132: 44-8.
Narayanan P, Nair S, Balwani M, Malinis M, Mistry P. The clinical spectrum of SARS-CoV-2 infection in Gaucher disease: effect of both a pandemic and a rare disease that disrupts the immune system. Mol Genet Metab 2021; S1096-7192(21)00768-X.
Andrade-Campos M, Escuder-Azuara B, de Frutos LL, Serrano-Gonzalo I, Giraldo P, GEEDL et al. Direct and indirect effects of the SARS-CoV-2 pandemic on Gaucher disease patients in Spain: time to reconsider home-based therapies? Blood Cells Mol Dis 2020; 85: 102478.
Annalisa S, Daniela M, Serena V, Maria DRR, Manuela Z, Alessandro S et al. Impact of COVID-19 related healthcare crisis on treatments for patients with lysosomal storage disorders, the first Italian experience. Mol Genet Metab 2020; 130: 170-1.
Zimran A, Szer J, Revel-Vilk S. Impact of Gaucher disease on COVID-19. Intern Med J 2020; 50: 894-5.
Fdil N. The lysosomal storage diseases: a promising axis for COVID-19 future therapies. Am J Biomed Sci Res 2020; 10: 570-1.
Valle DMD, Kim-Schulze S, Huang H-H, Beckmann ND, Nirenberg S, Wang B et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med 2020; 26: 1636-43.
Magage S, Lubanda J-C, Susa Z, Bultas J, Karetová D, Dobrovolný R et al. Natural history of the respiratory involvement in Anderson-Fabry disease. J Inherit Metab Dis 2007; 30: 790.
Ghosh S, Dellibovi-Ragheb TA, Kerviel A, Pak E, Qiu Q, Fisher M et al. β-Coronaviruses use lysosomes for egress instead of the biosynthetic secretory pathway. Cell 2020; 183: 1520-1535.e14.
Yekeduz MK, Kose E, Eminoglu FT. A case with Gaucher disease unable to reach enzyme replacement therapy because of COVID-19 quarantine: the first case from Turkey. Turkish Archives of Pediatrics. 2021; 56: 270-1.
Rajasekharan S, Bonotto RM, Alves LN, Kazungu Y, Poggianella M, Martinez-Orellana P et al. Inhibitors of protein glycosylation are active against the coronavirus severe acute respiratory syndrome coronavirus SARS-CoV-2. Viruses 2021; 13: 808.
Ginns EI, Ryan E, Sidransky E. Gaucher disease in the COVID-19 pandemic environment: the good, the bad and the unknown. Mol Genet Metab 2021; 132: 213-4.